Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate

OBJECTIVES: Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment. METHODS: Children aged 4–17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovell, Daniel J, Brunner, Hermine I, Reiff, Andreas O, Jung, Lawrence, Jarosova, Katerina, Němcová, Dana, Mouy, Richard, Sandborg, Christy, Bohnsack, John F, Elewaut, Dirk, Gabriel, Christos, Higgins, Gloria, Kone-Paut, Isabelle, Jones, Olcay Y, Vargová, Veronika, Chalom, Elizabeth, Wouters, Carine, Lagunes, Ivan, Song, Yanna, Martini, Alberto, Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425194/
https://www.ncbi.nlm.nih.gov/pubmed/32665432
http://dx.doi.org/10.1136/rmdopen-2020-001208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425194/
https://www.ncbi.nlm.nih.gov/pubmed/32665432
http://dx.doi.org/10.1136/rmdopen-2020-001208

Ejemplares similares